AGID is diagnosed with a complete medical history, exam of patients motility and with special blood tests looking for autoantibodies consistent with neurologic autoimmunity. Blood tests included evaluations of immunofluorescence (neuronal nuclear and cytoplasmic antibodies), radioimmunoprecipitation assays (neuronal and muscle plasma membrane cation channel antibodies), and enzyme-linked immunosorbent assay (muscle striational antibodies). A finding, along with medical history, of ganglionic neuronal acetylcholine receptor and N-type voltage-gated calcium channel autoantibodies in the blood stream would result in a medically acceptable diagnosis of AGID.

Pyridostigmine is a pharmaceutical treatment option for patients with AGID.

In severe cases patients with AGID are required to abandon eating foods, requiring them to get nourishment through a process called Parenteral nutrition, where the patient is fed via a permanent IV and the liquid nourishment is infused directly in the blood stream, as opposed to a feeding tube.